What this trial studies
This research will be conducted in a prospective pre-test post-test measurement randomized controlled experimental design. The population of the study consists of women who have entered menopause and live in Karabük. The research sample size was calculated considering the literature information that in experimental studies each group should consist of at least 30 individuals, taking into account the power of the test with G*Power 3.1 Program. It was calculated that at least 32 observations are needed in both the experimental and control groups to reach a power level of 90% at a significance level of 5% with an effect size of 0.75, and the sample size of the study was calculated as 64 women.
Conditions in scope
- Menopause
- Menopause Related Conditions
- Menopausal Depression
Interventions
- Intervention (Other) — 1. Process: implementation of pre-tests 2. Process: Solution-focused counseling, 60 minutes once a week for a total of 6 sessions 3. Final test after 2 months
Who can join
Women only · Ages 45 Years to 65 Years · Accepts healthy volunteers.
Inclusion criteria
- Accepting to participate in the study
- Being a woman
- Having been diagnosed with menopause for at least 1 year
Exclusion criteria
- Leaving work halfway through without filling out surveys or scales even though you stayed to work
- Having any barriers to communication
- Having received a psychiatric diagnosis
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Karabük | Karabük Province | Karabuk University | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2024-09-01
- Primary completion: 2025-07-03
- Last update posted: 2025-08-05
- First posted: 2024-09-03
Sponsor & contact
Lead sponsor: Karabuk University (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- prevention (One session per week, each session is 90 minutes, a total of 6 sessions.)
Menopausal complaints
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06582433 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.